Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Journal of the National Cancer Institute. 2012; 104: 93-113
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
Therapeutics and clinical risk management. 2022; 18: 683-698
Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
Targeted Oncology. 2020; 15: 549-565
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes
American Journal of Clinical Oncology. 2014; 37(4): 397-403
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies
Expert Opinion in Drug Safety. 2014; 13(4): 497-510
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor
Clinical genitourinary cancer. 2023; 21(5): e343-351
Optimizing the use of lenvatinib combination with pembrolizumab in patients with advanced endometrial carcinoma
Frontiers in Oncology. 2022; 12: 979519. doi: 10.3389/fonc.2022.979519
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
Journal of Clinical Oncology. 2022; 40(17): 1929-1938
Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice
Current Oncology. 2022; 29: 6776-6786
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
European Urology Oncology. 2022; 5(2): 225-234
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
The Oncologist. 2023; 28(6): 501-509
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
British Journal of Cancer. 2020; 123: 898-904
Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach
JCO Oncology Practice. 2020; 16 (Supp 1): 15s - 19s
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review
Cancer Treatment Reviews. 2020; 103: 102333
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
Oncologist. 2024; 29: 25-35
